Literature DB >> 12848949

Parvovirus B19 infection and autoimmune disease.

Hartwig W Lehmann1, Philipp von Landenberg, Susanne Modrow.   

Abstract

Human parvovirus B19 infections may cause a widespread benign and self-limiting disease in children and adults, known as erythema infectiosum or fifth disease. A variety of further manifestations are associated with the infection such as arthralgias, arthritis, leukopenia and thrombocytopenia, anemia and vasculitis, spontaneous abortion and hydrops fetalis in pregnant women. Both in children and adults parvovirus B19 infections have been frequently implicated as a cause or trigger of various forms of autoimmune diseases affecting joints, connective tissue and large and small vessels. In addition, autoimmune neutropenia, thrombocytopenia and hemolytic anemia are known as sequelae of B19 infection. The molecular basis of the autoimmune phenomena and resultant pathogenesis is unclear. The involvement of molecular mimicry between cellular and viral proteins, the induction of enhanced cytokine production via the viral transactivator protein NS1 and the phospholipase A2-like activity of the capsid protein VP1 may contribute to the induction of autoimmune reactions. All the known data and the potential mechanisms involved in the pathogenesis will be discussed in this review.

Entities:  

Mesh:

Year:  2003        PMID: 12848949     DOI: 10.1016/s1568-9972(03)00014-4

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  40 in total

1.  Human parvovirus B19 viraemia is associated with neither IgM positivity nor anaemia in patients with rheumatic diseases.

Authors:  Y Munakata; T Saito
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

2.  Visualization of the externalized VP2 N termini of infectious human parvovirus B19.

Authors:  Bärbel Kaufmann; Paul R Chipman; Victor A Kostyuchenko; Susanne Modrow; Michael G Rossmann
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

3.  Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity.

Authors:  Carlos Ros; Marco Gerber; Christoph Kempf
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

4.  Parvovirus B19 detected in Rosai-Dorfman disease in nodal and extranodal manifestations.

Authors:  Y Mehraein; M Wagner; K Remberger; L Füzesi; P Middel; S Kaptur; K Schmitt; E Meese
Journal:  J Clin Pathol       Date:  2006-12       Impact factor: 3.411

5.  Parvovirus B19 infection of human primary erythroid progenitor cells triggers ATR-Chk1 signaling, which promotes B19 virus replication.

Authors:  Yong Luo; Sai Lou; Xuefeng Deng; Zhengwen Liu; Yi Li; Steve Kleiboeker; Jianming Qiu
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

6.  Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity.

Authors:  Claudia Bönsch; Christoph Kempf; Carlos Ros
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

7.  Human parvovirus B19 nonstructural protein NS1 enhanced the expression of cleavage of 70 kDa U1-snRNP autoantigen.

Authors:  Bor-Show Tzang; Der-Yuan Chen; Chun-Chou Tsai; Szu-Yi Chiang; Tsung-Ming Lin; Tsai-Ching Hsu
Journal:  J Biomed Sci       Date:  2010-05-25       Impact factor: 8.410

8.  Clonal predominance of CD8(+) T cells in patients with unexplained neutropenia.

Authors:  Marcin Wojciech Wlodarski; Zachary Nearman; Ying Jiang; Alan Lichtin; Jaroslaw Pawel Maciejewski
Journal:  Exp Hematol       Date:  2008-03       Impact factor: 3.084

9.  Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells.

Authors:  T-C Hsu; B-S Tzang; C-N Huang; Y-J Lee; G-Y Liu; M-C Chen; G J Tsay
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

10.  Transient neutropenia in children with febrile illness and associated infectious agents: 2 years' follow-up.

Authors:  Ourania Alexandropoulou; Lydia Kossiva; Fotis Haliotis; Maria Giannaki; Maria Tsolia; I P Panagiotou; Kyriaki Karavanaki
Journal:  Eur J Pediatr       Date:  2013-02-14       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.